Bicara Therapeutics (BCAX) Cash from Financing Activities (2023 - 2026)

Bicara Therapeutics' Cash from Financing Activities history runs 4 years deep, the most recent figure standing at $163.3 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 35409.78% year-over-year to $163.3 million in Q1 2026; TTM through Mar 2026 was $195.1 million, a 41.63% decrease from a year earlier, with the FY2025 full-year figure at $32.3 million, down 90.34% from the prior year.
• Cash from Financing Activities grew to $163.3 million in Q1 2026 per BCAX's latest filing, from $31.2 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $334.1 million in Q3 2024 and bottomed at -$975000.0 in Q4 2024.
• The 4-year median for Cash from Financing Activities is $597000.0 (2024), against an average of $72.4 million.
• Across the five-year window, Cash from Financing Activities tumbled 100.5% in 2024 and jumped 35409.78% in 2026, its largest moves.
• Year by year, Cash from Financing Activities stood at $194.7 million in 2023, then tumbled by 100.5% to -$975000.0 in 2024, then surged by 3303.08% to $31.2 million in 2025, then soared by 423.04% to $163.3 million in 2026.
• Per Business Quant, the three latest BCAX Cash from Financing Activities figures stand at $163.3 million (Q1 2026), $31.2 million (Q4 2025), and $436000.0 (Q3 2025).